Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 8/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.37 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634040 | 0.83 | MC4R (0.55) | MC4RKCNQ2DPP4RAB9AP2RX7 | |
| SCHEMBL29011403 | 0.76 | CXCL8 (0.47) | CXCL8KCNQ2PTGS1PTGS2AKR1B10 | |
| SCHEMBL29163813 | 0.72 | METTL3 (0.46) | CXCL8KCNQ2PTGS1PTGS2AKR1B10 | |
| SCHEMBL9923328 | 0.72 | MC4R (0.72) | MC4RDPP4ADRA1A | |
| SCHEMBL2468867 | 0.72 | SLC6A4 (0.44) | CXCL8KCNQ2PTGS1PTGS2AKR1B10 | |
| SCHEMBL26193721 | 0.71 | CXCL8 (0.52) | CXCL8PTGS1PTGS2AKR1B10UGT1A9 | |
| SCHEMBL2739297 | 0.71 | CXCL8 (0.67) | CXCL8PTGS1PTGS2AKR1B10UGT1A9 | |
| SCHEMBL14451970 | 0.71 | DPP4 (0.50) | MC4RKCNQ2DPP4RAB9AP2RX7 | |
| SCHEMBL8276878 | 0.71 | DPP4 (0.50) | MC4RKCNQ2DPP4RAB9AP2RX7 | |
| SCHEMBL16509737 | 0.71 | DPP4 (0.75) | MC4RDPP4P2RX7CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170826-B1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS INC (US) | 2022-04-27 | — | — | EP | claimed |
| EP-4245752-A2 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | Techfields Inc (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| EP-2170826-B1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20190152991-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS PHARMA CO LTD (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10233198-B2 | Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses | TECHFIELDS PHARMA CO., LTD. (CN) | 2019-03-19 | — | — | US | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| US-20160272653-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS PHARMA CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-9371284-B2 | Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses | TECHFIELDS PHARMA CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | PREMIER RESEARCH INTERNATIONAL, LLC | 2010-07-08 | — | — | US | disclosed |
| EP-2170826-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | Techfields Inc (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| WO-2008149181-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS INC (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152991-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, SLC2A1, SLC2A2 | CXCL8 1698/4885MC4R 1411/4885KCNQ2 2712/4885 |
| US-10233198-B2 | Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses | MYLK2, ALPI, SLC2A2 | CXCL8 1267/4885MC4R 1649/4885KCNQ2 2984/4885 |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, ALPI, SLC2A2 | CXCL8 1267/4885MC4R 1649/4885KCNQ2 2984/4885 |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC19A1, HIRA, SLC43A1 | CXCL8 1056/4885MC4R 4514/4885KCNQ2 3462/4885 |
| US-20160272653-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, ALPI, SLC2A2 | CXCL8 1267/4885MC4R 1649/4885KCNQ2 2984/4885 |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CXCL8 187/4885MC4R 2882/4885KCNQ2 4192/4885 |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CXCL8 187/4885MC4R 2882/4885KCNQ2 4192/4885 |
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | CXCL8 1056/4885MC4R 4514/4885KCNQ2 3462/4885 |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CXCL8 187/4885MC4R 2882/4885KCNQ2 4192/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CXCL8 187/4885MC4R 2882/4885KCNQ2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.